Sex: U
Vaccine: COVID19
Symptoms: Audiogram, COVID-19, Deafness, Nystagmus, Rhinitis
Clinical narrative: I then later developed symptoms of a moderate hearing loss in my right ear; along with a low pitched tinnitus; transient rotational nystagmus; my symptoms of rhinitis worsened; I recently experienced my first symptomatic covid infection in december  2023/my symptoms of rhinitis worsened/ then i developed symptoms of moderate hearing loss in my right ear along with low pitched tinnitus; This spontaneous case was reported by a patient and describes the occurrence of DEAFNESS (I then later developed symptoms of a moderate hearing loss in my right ear) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Previously administered products included for COVID-19 prophylaxis: Moderna on 24-Jan-2021, Moderna on 21-Feb-2021, Moderna on 06-May-2021, Moderna on 22-Oct-2021 and Moderna Omicron Bivalent (Moderna Omicron Bivalent) on 12-Sep-2022; for Product used for unknown indication: Phizer 12+ Monovalent (Phizer 12 plus Monovalent) on 25-Apr-2022. Past adverse reactions to the above products included No adverse reaction with Moderna, Moderna, Moderna, Moderna, Moderna Omicron Bivalent and Phizer 12+ Monovalent.    On 03-Oct-2023, the patient received seventh dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced COVID-19 (I recently experienced my first symptomatic covid infection in december  2023/my symptoms of rhinitis worsened/ then i developed symptoms of moderate hearing loss in my right ear along with low pitched tinnitus). On an unknown date, the patient experienced DEAFNESS (I then later developed symptoms of a moderate hearing loss in my right ear) (seriousness criterion medically significant), TINNITUS (along with a low pitched tinnitus), NYSTAGMUS (transient rotational nystagmus) and RHINITIS (my symptoms of rhinitis worsened). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) in December 2023 for Symptomatic COVID-19, at an unspecified dose and frequency. At the time of the report, DEAFNESS (I then later developed symptoms of a moderate hearing loss in my right ear), TINNITUS (along with a low pitched tinnitus), NYSTAGMUS (transient rotational nystagmus), RHINITIS (my symptoms of rhinitis worsened) and COVID-19 (I recently experienced my first symptomatic covid infection in december  2023/my symptoms of rhinitis worsened/ then i developed symptoms of moderate hearing loss in my right ear along with low pitched tinnitus) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Audiogram: lost approximately of nearly all tested frequencies. On an unknown date, SARS-CoV-2 test: (Positive) until day 9 following symptom onset and (Positive) did not convert to negative status for another 9 days..         Concomitant medication was not reported.  It was reported that, patient experienced first symptomatic Covid infection and was given Paxlovid within 4 days of the onset of symptoms. Symptoms were mild. 304 days later, symptoms of rhinitis worsened, and rapid ag test was found to be positive. It did not convert to negative status for another 9 days. Patient later developed symptoms of a moderate hearing loss in right ear along with a low-pitched tinnitus and transient rotational nystagmus which lasted minutes but recurred several times over an hour period. Patient saw ENT specialist and an audiogram revealed had lost approximately of nearly all tested frequencies when compared to previous angiogram 15 months earlier. Ent physician had seen numerous patients who had suffered form long covid affecting the 8th cranial nerve following a covid infection. Ent physician told symptoms would likely resolve over several weeks and asked to recheck with hearing aid technician later this month.  Company comment: This is an spontaneous case concerning a patient of an unknown age and gender with medical history of Previously administered products included for COVID-19 prophylaxis: Moderna on 24-Jan, 21-Feb, 06-May, 22-Oct of 2021;  Moderna Omicron Bivalent on 12-Sep-2022; Pfizer 12+ Monovalent on 25-Apr-2022 with no adverse events who experienced  the seriousness criteria medically significant unexpected event of deafness; the unexpected events of  tinnitus, nystagmus, rhinitis and Covid-19 occurred after 7th. dose of mRNA-1273.815 vaccine. COVID-19 event occurred approximately 2 months after the mentioned dose; the other events occurred on unknown date after moderna vaccination. The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) in December 2023 for Symptomatic COVID-19. At the time of the report, the outcome of the events was unknown. The benefit-risk relationship of mRNA-1273.815 vaccine is not affected by this report.